



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 22-11-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE WEEKENDING 15-11-2008 TO BE PUBLISHED 24-11-2008 IN THE GAZETTE OF PAKISTAN PART-V.

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 22-11-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 15-11-2008 TO BE PUBLISHED 24-11-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1330/2008	<u>11-11-2008</u> Clipsal Australia Pty Limited, Austria (Priority 14-11-07 Hong Kong)	“Multi-conductor cable construction”
1331/2008	Sanofi-Aventis Deutschland GmbH, Germany (Priority 13-11-07 Germany)	“Novel crystalline diphenylazetidinone hydrates, medicaments comprising these compounds and use thereof”
1332/2008	<u>12-11-2008</u> Janssen Pharmaceutica N.V., Belgium (Priority 14-11-07 Europe)	“Equilibrative nucleoside transporter enti inhibitors”
1333/2008	1.Siemens VAI Metals Technologies GmbH & Co., Austria 2. POSCO, KOREA (Priority 13-11-07 AT)	“Method for production and the melting of liquid pig iron or of liquid steel intermediate products in a meltdown gasifier”
1334/2008	Sanofi-Aventis France (Priority 09-11-07 France)	“Pharmaceutical compositions based on azetidine derivatives”
1335/2008	BASF SE Germany (Priority 14-11-07 Europe)	“Foamed polyurethanes having improved flexing endurance properties”
1336/2008	<u>13-11-2008</u> H. Lundbeck A/S., Denmark (Priority 13-11-07 Denmark)	“Therapeutic uses of compounds having combined SERT, 5-HT ₃ and 5-HT _{1A} activity”
1337/2008	1. Evec Inc.	“Monoclonal antibodies that bind to

	<p>Japan 2. Boehringer Ingelheim International GmbH Germany (Priority 13-11-07 Japan)</p>	<p>hGM-CSF and medical compositions comprising same”</p>
1338/2008	<p>Boehringer Ingelheim International GmbH Germany (Priority 16-11-07 USA)</p>	<p>“Inhibitors of human immunodeficiency virus replication”</p>
1339/2008	<p>Sanofi-Aventis Deutschland GmbH, Germany (Priority 24-10-03 Germany) Divisional</p>	<p>“A physiologically tolerated salt of a substituted bengamide compound”</p>
1340/2008	<p><u>14-11-2008</u> MARICAP OY Pohjantahdentie Finland (Priority 14-11-07 Finland)</p>	<p>“Method for closing a waste bin filling hole and a waste bin”</p>
1341/2008	<p><u>15-11-2008</u> Huawei Technologies Co., Ltd. China (Priority 16-11-07 China)</p>	<p>“Method and apparatus for implementing the CNAP service”</p>
1342/2008	<p>ImClone Systems Incorporated, USA (Priority 21-11-07 USA)</p>	<p>“Inhibition of macrophages-stimulating protein receptor (RON) and methods of treatment thereof”</p>
1343/2008	<p>Monsanto Technology LLC, USA (Priority 15-11-07 USA)</p>	<p>“Soybean plant and seed corresponding to transgenic event mon87701 and methods for detection thereof”</p>
1344/2008	<p>AstraZeneca AB, Sweden (Priority 15-11-07 USA)</p>	<p>“BIS-(Sulfonylamino) derivatives in therapy 065”</p>
1345/2008	<p>AstraZeneca AB, Sweden (Priority 15-11-07 USA)</p>	<p>“BIS-(Sulfonylamino) derivatives in therapy 066”</p>

1346/2008

Mr. Mehboob Shahid Khan “KERBSTONES”
I.T. & P. Services, Lahore,
PAKISTAN

XXXXXXXXXX

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

241/2000	AstraZeneca UK Limited United Kingdom	“Amide compound” (CO7D, 401/12)
----------	---	--

139854

The invention concerns amide compound of the Formula Ia



Ia

wherein X is -NHCO- or -CONH- ;

m is 0-3;

R¹ is a group such as hydroxy , halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl;

n is 0-2;

R² is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and carboxy;

R³ is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy;

q is 0-4; and


Q is a group such as aryl, aryloxy, aryl-(1-

6C)alkoxy, arylamino and N-(1-6C)alkyl-
 arylamino;
 pharmaceutical composition containing it and its
 use in the treatment of diseases or medical
 conditions mediated by cytokines.

795/2000 SmithKline Beecham “A substituted phenylbutyrate compound”
 Corporation,
 USA. (A61K, 31/44, CO7D, 417/08)

139855


Compound of the formula (I) are disclosed which
 are vitronectin receptor antagonists and are useful
 in the treatment of osteoporosis:



Wherein:

R¹ is Het- or Ar;

R² is



125/2002 Syngenta
 Participations AG.,
 Switzerland “A herbicidal composition composing 2-(4-(3-
 chloro-5-fluoro-2-pyridyloxy)-phenoxy-propionic
 acid propargyl ester”

(AO1N, 25/02)

139856

A herbicidal composition in the form of an aqueous
 emulsion which comprises, as organic phase, a
 solution of a herbicidally effective amount of the
 compound 2-(4-(3-chloro-5-fluoro-2-pyridyloxy)-
 phenoxy-propionic acid propargyl ester in a
 hydrophobic solvent and a substantially water-
 insoluble and hydrolysis-stable oil phase stabiliser
 and, as aqueous phase, a solution of a pH buffer
 and at least one surface-active compound and/or
 dispersing agent in water.

826/2002 BASF
Aktiengesellschaft.,
Germany

“A crystalline hydrate of a substituted
nicotinanilide compound”

(CO7D, 277/82, CO7D, 213/82)

139857

The present invention relates to crystalline hydrate substituted nicotinanilide compound, and to its use for controlling phytopathogenic fungi or undesired attack by insects or mites and/or for regulating the growth of plants.


679/2004 Mitsubishi Tanabe
Pharma Corporation,
Japan

“An amide-type carboxamide compound”


(CO7D, 333/40)

139858

The present invention provide an amide-type carboxamide compound of the formula [I]:



Wherein X is a group of the formula: -N= or the formula: -CH=; R¹ is a halogen atom, a lower alkyl group, and the like; R² is a group of the formula:



And the like; Y¹ and Y² are the same of different and each is a group selected from a halogen atom, a lower alkyl group, a lower alkoxy group, and the like; Ring A is phenyl group, and the like, which is useful as an inhibitor of Fxa.

1022/2005 Syngenta
Participations, AG.,
Switzerland

“A process for the preparation of [1,4,5]-
oxadiazepine compound”

(CO7D, 273/06)

139859

A process for the preparation of [1,4,5]-
oxadiazepine derivative by reaction of 4,5-diacyl-
[1,4,5]-oxadiazepines with a base.

④④④④④④④④

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139512	Merck & Co., Inc. USA	690/1998
139513	SmithKline Beecham p.l.c. United Kingdom	1272/1998
139514	Wyeth., USA	390/1999
139515	Merck Patent GmbH., Germany	639/2000
139516	Aventis CropScience GmbH., Germany	307/2002
139517	Warner-Lambert Company LLC., USA	254/2003
139518	Wyeth. USA	895/2006
139519	Warner-Lambert Company LLC., USA	367/2007

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488